South Korea's AhnGook Pharmaceutical, traditionally known for its respiratory drug Sinechura, is diversifying into medical aesthetics and reinforcing its cardiovascular portfolio. The company recently added cosmetic surgery and biomedical product development to its business objectives, signaling a strategic pivot that overseas aesthetic device and injectable distributors should monitor for potential partnership or sourcing opportunities.
## Strategic diversification into medical aesthetics
At its March regular shareholders' meeting, AhnGook amended its articles of incorporation to include the development, manufacturing, and sale of cosmetic surgery-related preparations and biomedical products. The company has also begun recruiting personnel with experience in dermatology and plastic surgery sales, centralizing these efforts under a newly formed skin aesthetics business division.
## Cardiovascular portfolio gains momentum
AhnGook's cardiovascular drug lineup is showing strong growth. In Q1 2026, its dyslipidemia treatment Pebarozet generated approximately KRW 11.2 billion in sales, surpassing the KRW 8.1 billion from its legacy respiratory product Sinechura. The company also holds hypertension and dyslipidemia products such as Levotension, Subarzet, and Levosaltan, and in April obtained approval for Levosaltan Plus Tab, Korea's first indapamide-based triple combination hypertension therapy.
## Financial performance and market context
AhnGook reported steady revenue growth from KRW 233.7 billion in 2023 to KRW 271.1 billion in 2024, reaching KRW 306.9 billion in 2025. Operating profit rose from KRW 5.1 billion to KRW 9.8 billion over the same period. The company faces headwinds from domestic drug price cuts and generic competition, making portfolio diversification a key survival strategy.
## What buyers should watch
For overseas importers and distributors in medical aesthetics, AhnGook's entry into cosmetic surgery and biomedical products could open new OEM or partnership avenues. The company's established manufacturing capabilities and distribution network in Korea may appeal to clinics and suppliers seeking reliable Asian partners for aesthetic injectables or devices. However, specific product details and regulatory timelines remain undisclosed.
## Management vision
CEO Park In-chul outlined four growth pillars in his New Year's address: timely supply of quality products, securing cost advantages, market differentiation, and expanding customer experience. AhnGook aims to maintain its respiratory drug base while building new revenue streams in cardiovascular drugs and medical aesthetics.